A. Aouba and E. Eb, Données sur la mortalité en France : principales causes de décès en 2008 et évolutions depuis 2000 Bulletin épidémioloque hebdomadaireInduction of anchorage-independent growth by amphiregulin, Growth Factors, vol.22, issue.13, pp.249-2553, 1996.

C. Adrain and S. J. Martin, The mitochondrial apoptosome: a killer unleashed by the cytochrome seas, Trends in Biochemical Sciences, vol.26, issue.6, pp.390-397, 2001.
DOI : 10.1016/S0968-0004(01)01844-8

G. I. Aldana-masangkay and K. M. Sakamoto, The Role of HDAC6 in Cancer, Journal of Biomedicine and Biotechnology, vol.421, issue.6920, p.875824, 2011.
DOI : 10.1091/mbc.E06-01-0008

J. Amann and S. Kalyankrishna, Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer, Cancer Res, vol.65, issue.1, pp.226-235, 2005.

S. Aoyagi and T. K. Archer, Modulating molecular chaperone Hsp90 functions through reversible acetylation, Trends in Cell Biology, vol.15, issue.11, pp.565-567, 2005.
DOI : 10.1016/j.tcb.2005.09.003

C. L. Arteaga, Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression?, The Oncologist, vol.7, issue.90004, pp.31-39, 2002.
DOI : 10.1634/theoncologist.7-suppl_4-31

H. Asahina and K. Yamazaki, A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations, British Journal of Cancer, vol.311, issue.8, pp.998-1004, 2006.
DOI : 10.1093/annonc/mdi340

A. Ashkenazi and V. M. Dixit, Death Receptors: Signaling and Modulation, Science, vol.281, issue.5381, pp.1305-1308, 1998.
DOI : 10.1126/science.281.5381.1305

J. L. Avalos and K. M. Bever, Mechanism of Sirtuin Inhibition by Nicotinamide: Altering the NAD+ Cosubstrate Specificity of a Sir2 Enzyme, Molecular Cell, vol.17, issue.6, pp.855-868, 2005.
DOI : 10.1016/j.molcel.2005.02.022

M. N. Balak and Y. Gong, Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors, Clinical Cancer Research, vol.12, issue.21, pp.6494-6501, 2006.
DOI : 10.1158/1078-0432.CCR-06-1570

P. Bali and M. Pranpat, Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90: A NOVEL BASIS FOR ANTILEUKEMIA ACTIVITY OF HISTONE DEACETYLASE INHIBITORS, Journal of Biological Chemistry, vol.280, issue.29, pp.26729-26734, 2005.
DOI : 10.1074/jbc.C500186200

M. Barbacid, ras Genes, Annual Review of Biochemistry, vol.56, issue.1, pp.779-827, 1987.
DOI : 10.1146/annurev.bi.56.070187.004023

M. Barry and R. C. Bleackley, Cytotoxic T lymphocytes: all roads lead to death, Nat Rev Immunol, vol.2, issue.6, pp.401-409, 2002.

J. Bean and C. Brennan, MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib, Proceedings of the National Academy of Sciences, vol.104, issue.52, pp.20932-20937, 2007.
DOI : 10.1073/pnas.0710370104

M. B. Beasley and E. Brambilla, The 2004 World Health Organization classification of lung tumors, Seminars in Roentgenology, vol.40, issue.2, pp.90-97, 2005.
DOI : 10.1053/j.ro.2005.01.001

A. Belot and M. Velten, Estimation nationale de l'incidence et de la mortalité par cancer en France entre Institut de veille sanitaire 132pEpidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities, J Biol Chem, vol.271, issue.11, pp.6071-6076, 1980.

S. L. Berger, Molecular biology. The histone modification circus, Science, vol.292, issue.5514, pp.64-65, 2001.

N. R. Bertos and B. Gilquin, Role of the Tetradecapeptide Repeat Domain of Human Histone Deacetylase 6 in Cytoplasmic Retention, Journal of Biological Chemistry, vol.279, issue.46, pp.48246-48254, 2004.
DOI : 10.1074/jbc.M408583200

C. Birchmeier and W. Birchmeier, Met, metastasis, motility and more, Nature Reviews Molecular Cell Biology, vol.4, issue.12, pp.915-925, 2003.
DOI : 10.1038/nrm1261

B. L. Black and E. N. Olson, TRANSCRIPTIONAL CONTROL OF MUSCLE DEVELOPMENT BY MYOCYTE ENHANCER FACTOR-2 (MEF2) PROTEINS, Annual Review of Cell and Developmental Biology, vol.14, issue.1, pp.167-196, 1998.
DOI : 10.1146/annurev.cellbio.14.1.167

M. A. Blasco, Opinion: Telomerase beyond telomeres, Nature Reviews Cancer, vol.2, issue.8, pp.627-633, 2002.
DOI : 10.1038/nrc862

J. L. Bodmer and N. Holler, TRAIL receptor-2 signals apoptosis through FADD and caspase- 8, Nat Cell Biol, vol.2, issue.4, pp.241-243, 2000.

E. Brambilla and A. Gazdar, Pathogenesis of lung cancer signalling pathways: roadmap for therapies, European Respiratory Journal, vol.33, issue.6, pp.1485-1497, 2009.
DOI : 10.1183/09031936.00014009

J. J. Buggy and M. L. Sideris, Cloning and characterization of a novel human histone deacetylase, HDAC8, Biochem J 350 Pt, vol.1, pp.199-205, 2000.

D. Buglio and N. M. Khaskhely, HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma, Blood, vol.117, issue.10, pp.2910-2917, 2011.
DOI : 10.1182/blood-2010-08-303701

A. W. Burgess and H. S. Cho, An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors, Molecular Cell, vol.12, issue.3, pp.541-552, 2003.
DOI : 10.1016/S1097-2765(03)00350-2

B. Busser and L. Sancey, The multiple roles of amphiregulin in human cancer, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1816, issue.2, pp.119-131, 2011.
DOI : 10.1016/j.bbcan.2011.05.003

URL : https://hal.archives-ouvertes.fr/inserm-00602082

B. Busser and L. Sancey, Amphiregulin Promotes BAX Inhibition and Resistance to Gefitinib in Non-small-cell Lung Cancers, Molecular Therapy, vol.18, issue.3, pp.528-535, 2010.
DOI : 10.1038/mt.2009.226

URL : https://hal.archives-ouvertes.fr/inserm-00425468

B. Busser and L. Sancey, Amphiregulin Promotes Resistance to Gefitinib in NonSmall Cell Lung Cancer Cells by Regulating Ku70 Acetylation, Molecular Therapy, vol.18, issue.3, pp.536-543, 2010.
DOI : 10.1038/mt.2009.227

URL : https://hal.archives-ouvertes.fr/inserm-00425467

K. V. Butler and J. Kalin, Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A, Journal of the American Chemical Society, vol.132, issue.31, pp.10842-10846, 2010.
DOI : 10.1021/ja102758v

F. Cappuzzo and F. R. Hirsch, Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non-Small-Cell Lung Cancer, JNCI Journal of the National Cancer Institute, vol.97, issue.9, pp.643-655, 2005.
DOI : 10.1093/jnci/dji112

F. Cappuzzo and M. Varella-garcia, Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor???Positive Non???Small-Cell Lung Cancer Patients, Journal of Clinical Oncology, vol.23, issue.22, pp.5007-5018, 2005.
DOI : 10.1200/JCO.2005.09.111

F. Cappuzzo and T. Ciuleanu, Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study, The Lancet Oncology, vol.11, issue.6, pp.521-529, 2010.
DOI : 10.1016/S1470-2045(10)70112-1

A. A. Carmen and P. R. Griffin, Yeast HOS3 forms a novel trichostatin A-insensitive homodimer with intrinsic histone deacetylase activity, Proceedings of the National Academy of Sciences, vol.96, issue.22, pp.96-12356, 1999.
DOI : 10.1073/pnas.96.22.12356

G. Carpenter, L. King, and . Jr, Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro, Nature, vol.199, issue.5686, pp.409-410, 1978.
DOI : 10.1016/0014-5793(77)80489-4

V. Catros-quemener and F. Bouet, Immunit?? anti-tumorale et th??rapies cellulaires du cancer, m??decine/sciences, vol.19, issue.1, pp.43-53, 2003.
DOI : 10.1051/medsci/200319143

J. E. Chipuk and D. R. Green, Dissecting p53-dependent apoptosis, Cell Death and Differentiation, vol.285, issue.6, pp.994-1002, 2006.
DOI : 10.1038/sj.cdd.4401908

E. Chung and P. W. Cook, Amphiregulin Causes Functional Downregulation of Adherens Junctions in Psoriasis, Journal of Investigative Dermatology, vol.124, issue.6, pp.1134-1140, 2005.
DOI : 10.1111/j.0022-202X.2005.23762.x

A. Citri and K. B. Skaria, The deaf and the dumb: the biology of ErbB-2 and ErbB-3, Experimental Cell Research, vol.284, issue.1, pp.54-65, 2003.
DOI : 10.1016/S0014-4827(02)00101-5

P. G. Clarke and A. Posada, Neuronal death in the central nervous system during development, Biomedicine & Pharmacotherapy, vol.52, issue.9, pp.356-362, 1998.
DOI : 10.1016/S0753-3322(99)80002-X

H. Y. Cohen and S. Lavu, Acetylation of the C Terminus of Ku70 by CBP and PCAF Controls Bax-Mediated Apoptosis, Molecular Cell, vol.13, issue.5, pp.627-638, 2004.
DOI : 10.1016/S1097-2765(04)00094-2

D. E. Comings, A General Theory of Carcinogenesis, Proceedings of the National Academy of Sciences, vol.70, issue.12, pp.3324-3328, 1973.
DOI : 10.1073/pnas.70.12.3324

O. Cooper and G. Vlotides, Expression and function of ErbB receptors and ligands in the pituitary, Endocrine Related Cancer, vol.18, issue.6, pp.197-211, 2011.
DOI : 10.1530/ERC-11-0066

S. Cory and J. M. Adams, The bcl2 family: regulators of the cellular life-or-death switch, Nature Reviews Cancer, vol.2, issue.9, pp.647-656, 2002.
DOI : 10.1038/nrc883

M. S. Cosgrove and J. D. Boeke, Regulated nucleosome mobility and the histone code, Nature Structural & Molecular Biology, vol.21, issue.11, pp.1037-1043, 2004.
DOI : 10.1101/gad.872801

D. B. Costa and B. Halmos, BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations, PLoS Medicine, vol.25, issue.10, pp.1669-1679, 2007.
DOI : 10.1371/journal.pmed.0040315.st001

E. M. Creagh and H. Conroy, Caspase-activation pathways in apoptosis and immunity, Immunological Reviews, vol.8, issue.1, pp.10-21, 2003.
DOI : 10.1074/jbc.M101415200

W. D. Cress and E. Seto, Histone deacetylases, transcriptional control, and cancer, Journal of Cellular Physiology, vol.271, issue.1, pp.1-16, 2000.
DOI : 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7

L. Crino and F. Cappuzzo, Gefitinib Versus Vinorelbine in Chemotherapy-Na??ve Elderly Patients With Advanced Non???Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study, Journal of Clinical Oncology, vol.26, issue.26, pp.4253-4260, 2008.
DOI : 10.1200/JCO.2007.15.0672

T. Cufer and E. Vrdoljak, Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer, Anti-Cancer Drugs, vol.17, issue.4, pp.401-409, 2006.
DOI : 10.1097/01.cad.0000203381.99490.ab

B. Dautzenberg and G. Choukroun, Cancers bronchopulmonaires primitifs non à petites cellules et tumeurs à malignité réduite EMC-pneumologie (6-002-H-20): 16 p D'Incecco, A. and FGefitinib for non-small-cell lung cancer treatment, Cappuzzo Expert Opin Drug Saf, vol.10, issue.6, pp.987-96, 1998.

D. Luca, A. , and A. Casamassimi, EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells, Int J Cancer, vol.80, issue.4, pp.589-594, 1999.

K. M. Debatin and P. H. Krammer, Death receptors in chemotherapy and cancer, Oncogene, vol.23, issue.16, pp.2950-2966, 2004.
DOI : 10.1038/sj.onc.1207558

J. Downward, Targeting RAS signalling pathways in cancer therapy, Nature Reviews Cancer, vol.3, issue.1, pp.11-22, 2003.
DOI : 10.1038/nrc969

M. J. Duffy and E. Mckiernan, Role of ADAMs in Cancer Formation and Progression, Clinical Cancer Research, vol.15, issue.4, pp.1140-1144, 2009.
DOI : 10.1158/1078-0432.CCR-08-1585

W. C. Earnshaw and L. M. Martins, Mammalian Caspases: Structure, Activation, Substrates, and Functions During Apoptosis, Annual Review of Biochemistry, vol.68, issue.1, pp.383-424, 1999.
DOI : 10.1146/annurev.biochem.68.1.383

D. A. Eberhard and B. E. Johnson, Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non???Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib, Journal of Clinical Oncology, vol.23, issue.25, pp.5900-5909, 2005.
DOI : 10.1200/JCO.2005.02.857

D. Eilstein and Z. Uhry, Lung cancer mortality in France, Lung Cancer, vol.59, issue.3, pp.282-290, 2008.
DOI : 10.1016/j.lungcan.2007.10.012

J. A. Engelman and K. Zejnullahu, MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling, Science, vol.316, issue.5827, pp.1039-1043, 2007.
DOI : 10.1126/science.1141478

K. Erjala and M. Sundvall, Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells, Clinical Cancer Research, vol.12, issue.13, pp.4103-4111, 2006.
DOI : 10.1158/1078-0432.CCR-05-2404

I. Fernandes and Y. Bastien, Ligand-Dependent Nuclear Receptor Corepressor LCoR Functions by Histone Deacetylase-Dependent and -Independent Mechanisms, Molecular Cell, vol.11, issue.1, pp.139-150, 2003.
DOI : 10.1016/S1097-2765(03)00014-5

URL : http://doi.org/10.1016/s1097-2765(03)00014-5

S. W. Fesik, Promoting apoptosis as a strategy for cancer drug discovery, Nature Reviews Cancer, vol.88, issue.11, pp.876-885, 2005.
DOI : 10.1038/nrc1361

M. S. Finnin and J. R. Donigian, Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors, Nature, vol.401, issue.6749, pp.188-193, 1999.

R. N. Freiman and R. Tjian, Regulating the Regulators, Cell, vol.112, issue.1, pp.11-17, 2003.
DOI : 10.1016/S0092-8674(02)01278-3

D. W. Fry, Mechanism of action of erbB tyrosine kinase inhibitors, Experimental Cell Research, vol.284, issue.1, pp.131-139, 2003.
DOI : 10.1016/S0014-4827(02)00095-2

M. Fukuoka and S. Yano, Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.21, issue.12, pp.2237-2246, 2003.
DOI : 10.1200/JCO.2003.10.038

S. C. Galasinski and K. A. Resing, Phosphatase Inhibition Leads to Histone Deacetylases 1 and 2 Phosphorylation and Disruption of Corepressor Interactions, Journal of Biological Chemistry, vol.277, issue.22, pp.19618-19626, 2002.
DOI : 10.1074/jbc.M201174200

U. Gatzemeier, A. Pluzanska, and A. , Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non???Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial, Journal of Clinical Oncology, vol.25, issue.12, pp.1545-52, 2007.
DOI : 10.1200/JCO.2005.05.1474

L. Gao and M. A. Cueto, Cloning and Functional Characterization of HDAC11, a Novel Member of the Human Histone Deacetylase Family, Journal of Biological Chemistry, vol.277, issue.28, pp.25748-25755, 2002.
DOI : 10.1074/jbc.M111871200

Y. S. Gao and C. C. Hubbert, The Microtubule-associated Histone Deacetylase 6 (HDAC6) Regulates Epidermal Growth Factor Receptor (EGFR) Endocytic Trafficking and Degradation, Journal of Biological Chemistry, vol.285, issue.15, pp.11219-11226, 2010.
DOI : 10.1074/jbc.M109.042754

I. E. Garcia-de-palazzo and G. P. Adams, Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas, Cancer Res, vol.53, issue.14, pp.3217-3220, 1993.

D. Girdwood and D. Bumpass, p300 Transcriptional Repression Is Mediated by SUMO Modification, Molecular Cell, vol.11, issue.4, pp.1043-1054, 2003.
DOI : 10.1016/S1097-2765(03)00141-2

P. Goldstraw and J. Crowley, The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours, Journal of Thoracic Oncology, vol.2, issue.8, pp.706-714, 2007.
DOI : 10.1097/JTO.0b013e31812f3c1a

H. Greulich and T. H. Chen, Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants, PLoS Medicine, vol.57, issue.11, p.313, 2005.
DOI : 10.1371/journal.pmed.0020313.t002

URL : http://doi.org/10.1371/journal.pmed.0020313

C. M. Grozinger and C. A. Hassig, Three proteins define a class of human histone deacetylases related to yeast Hda1p, Proceedings of the National Academy of Sciences, vol.96, issue.9, pp.4868-4873, 1999.
DOI : 10.1073/pnas.96.9.4868

A. R. Guardiola and T. P. Yao, Molecular Cloning and Characterization of a Novel Histone Deacetylase HDAC10, Journal of Biological Chemistry, vol.277, issue.5, pp.3350-3356, 2002.
DOI : 10.1074/jbc.M109861200

I. Guessous and J. Cornuz, Lung cancer screening: current situation and perspective, Swiss Med Wkly, vol.137, pp.21-22, 2007.

S. J. Haggarty and K. M. Koeller, Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation, Proceedings of the National Academy of Sciences, vol.100, issue.8, pp.4389-4394, 2003.
DOI : 10.1073/pnas.0430973100

D. Hanahan and R. A. Weinberg, The Hallmarks of Cancer, Cell, vol.100, issue.1, pp.57-70, 2000.
DOI : 10.1016/S0092-8674(00)81683-9

T. Heinzel and R. M. Lavinsky, A complex containing N-CoR, mSln3 and histone deacetylase mediates transcriptional repression, nature, vol.387, issue.6628, pp.43-48, 1997.
DOI : 10.1038/387043a0

R. S. Herbst, P. A. Bunn, and J. , Targeting the epidermal growth factor receptor in non-small cell lung cancer, Clin Cancer Res, vol.916, issue.1, pp.5813-5824, 2003.

R. S. Herbst and J. V. Heymach, Lung Cancer, New England Journal of Medicine, vol.359, issue.13, pp.1367-1380, 2008.
DOI : 10.1056/NEJMra0802714

I. Herr and K. M. Debatin, Cellular stress response and apoptosis in cancer therapy, Blood, vol.98, issue.9, pp.2603-2614, 2001.
DOI : 10.1182/blood.V98.9.2603

C. Hill and F. Doyon, Évolution de la mortalité par cancer en France de Saint- Maurice (Fra) : Institut de veille sanitaire. 272p. Disponible sur: www.invs.santéEpidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis, J Clin Oncol, vol.21, issue.20, pp.3798-3807, 1950.

F. R. Hirsch and M. Varella-garcia, Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib, Annals of Oncology, vol.18, issue.4, pp.752-760, 2007.
DOI : 10.1093/annonc/mdm003

F. R. Hirsch and M. Varella-garcia, Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study, Journal of Clinical Oncology, vol.23, issue.28, pp.6838-6845, 2005.
DOI : 10.1200/JCO.2005.01.2823

T. Holbro and G. Civenni, The ErbB receptors and their role in cancer progression, Experimental Cell Research, vol.284, issue.1, pp.99-110, 2003.
DOI : 10.1016/S0014-4827(02)00099-X

T. Holbro and N. E. Hynes, : Directing Key Signaling Networks Throughout Life, Annual Review of Pharmacology and Toxicology, vol.44, issue.1, pp.195-217, 2004.
DOI : 10.1146/annurev.pharmtox.44.101802.121440

S. S. Hook and A. Orian, Histone deacetylase 6 binds polyubiquitin through its zinc finger (PAZ domain) and copurifies with deubiquitinating enzymes, Proceedings of the National Academy of Sciences, vol.99, issue.21, pp.99-13425, 2002.
DOI : 10.1073/pnas.172511699

E. Hu and Z. Chen, Cloning and Characterization of a Novel Human Class I Histone Deacetylase That Functions as a Transcription Repressor, Journal of Biological Chemistry, vol.275, issue.20, pp.15254-15264, 2000.
DOI : 10.1074/jbc.M908988199

C. Hubbert and A. Guardiola, HDAC6 is a microtubule-associated deacetylase, Nature, vol.417, issue.6887, pp.455-458, 2002.
DOI : 10.1038/417455a

A. Hurbin and J. L. Coll, Cooperation of Amphiregulin and Insulin-like Growth Factor-1 Inhibits Bax- and Bad-mediated Apoptosis via a Protein Kinase C-dependent Pathway in Non-small Cell Lung Cancer Cells, Journal of Biological Chemistry, vol.280, issue.20, pp.19757-19767, 2005.
DOI : 10.1074/jbc.M413516200

URL : https://hal.archives-ouvertes.fr/inserm-00340599

A. Hurbin and L. Dubrez, Inhibition of Apoptosis by Amphiregulin via an Insulin-like Growth Factor-1 Receptor-dependent Pathway in Non-small Cell Lung Cancer Cell Lines, Journal of Biological Chemistry, vol.277, issue.51, pp.49127-49133, 2002.
DOI : 10.1074/jbc.M207584200

A. Hurbin and M. Wislez, Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma, The Journal of Pathology, vol.3, issue.1, pp.83-95, 2011.
DOI : 10.1002/path.2897

URL : https://hal.archives-ouvertes.fr/inserm-00598462

N. E. Hynes and H. A. Lane, ERBB receptors and cancer: the complexity of targeted inhibitors, Nature Reviews Cancer, vol.7, issue.5, pp.341-354, 2005.
DOI : 10.1021/jm00130a020

S. Imai and L. Guarente, Ten years of NAD-dependent SIR2 family deacetylases: implications for metabolic diseases, Trends in Pharmacological Sciences, vol.31, issue.5, pp.212-220, 2010.
DOI : 10.1016/j.tips.2010.02.003

. Inca, Cancer du poumon Prise en charge thérapeutique du cancer du poumon non à petites cellules. Institut Nationale du Cancer 30p, 2010.

A. Inoue and T. Suzuki, Prospective Phase II Study of Gefitinib for Chemotherapy-Na??ve Patients With Advanced Non???Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations, Journal of Clinical Oncology, vol.24, issue.21, pp.3340-3346, 2006.
DOI : 10.1200/JCO.2005.05.4692

N. and Y. Daigo, Projection de l'incidence et de la mortalité par cancer en France en 2011 Rapport technique Saint-Maurice: Institut de veille sanitaire 78 p. Disponible sur: www.invs.santé.fr IshikawaIncreases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers, InVS Cancer Res, vol.65, issue.20, pp.9176-9184, 2005.

M. Jeffers and L. Schmidt, Activating mutations for the Met tyrosine kinase receptor in human cancer, Proceedings of the National Academy of Sciences, vol.94, issue.21, pp.11445-11450, 1997.
DOI : 10.1073/pnas.94.21.11445

R. W. Johnstone and A. A. Ruefli, Apoptosis, Cell, vol.108, issue.2, pp.153-164, 2002.
DOI : 10.1016/S0092-8674(02)00625-6

S. Kakiuchi and Y. Daigo, Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839), Human Molecular Genetics, vol.13, issue.24, pp.3029-3043, 2004.
DOI : 10.1093/hmg/ddh331

K. Kamemura and A. Ito, Effects of downregulated HDAC6 expression on the proliferation of lung cancer cells, Biochemical and Biophysical Research Communications, vol.374, issue.1, pp.84-89, 2008.
DOI : 10.1016/j.bbrc.2008.06.092

H. Y. Kao and M. Downes, Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression, Genes Dev, vol.14, issue.1, pp.55-66, 2000.

P. Karagianni and J. Wong, HDAC3: taking the SMRT-N-CoRrect road to repression, Oncogene, vol.158, issue.37, pp.5439-5449, 2007.
DOI : 10.1128/MCB.24.12.5106-5118.2004

A. Kariagina and J. Xie, Amphiregulin Mediates Estrogen, Progesterone, and EGFR Signaling in the Normal Rat Mammary Gland and in Hormone-Dependent Rat Mammary Cancers, Hormones and Cancer, vol.150, issue.Suppl 1, pp.229-244, 2010.
DOI : 10.1007/s12672-010-0048-0

M. Kato and T. Inazu, Amphiregulin is a potent mitogen for the vascular smooth muscle cell line, A7r5, Biochemical and Biophysical Research Communications, vol.301, issue.4, pp.1109-1115, 2003.
DOI : 10.1016/S0006-291X(03)00093-7

S. H. Kaufmann and W. C. Earnshaw, Induction of Apoptosis by Cancer Chemotherapy, Experimental Cell Research, vol.256, issue.1, pp.42-49, 2000.
DOI : 10.1006/excr.2000.4838

P. Keohavong and M. A. Demichele, Detection of K-ras mutations in lung carcinomas: relationship to prognosis, Clin Cancer Res, vol.2, issue.2, pp.411-418, 1996.

E. S. Kim and V. Hirsh, Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial, The Lancet, vol.372, issue.9652, pp.1809-1818, 2008.
DOI : 10.1016/S0140-6736(08)61758-4

T. Klikovits and A. End, Effects of reclassification from the TNM-6 into the TNM-7 staging system in bronchoplastic resection for non-small cell lung cancer, Interactive CardioVascular and Thoracic Surgery, vol.13, issue.1, pp.29-34, 2011.
DOI : 10.1510/icvts.2011.267021

S. Kobayashi and T. J. Boggon, Mutation and Resistance of Non???Small-Cell Lung Cancer to Gefitinib, New England Journal of Medicine, vol.352, issue.8, pp.786-792, 2005.
DOI : 10.1056/NEJMoa044238

M. G. Kris and R. B. Natale, Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non???Small Cell Lung Cancer, JAMA, vol.290, issue.16, pp.2149-2158, 2003.
DOI : 10.1001/jama.290.16.2149

I. L. Lai and T. P. Lin, Histone Deacetylase 10 Relieves Repression on the Melanogenic Program by Maintaining the Deacetylation Status of Repressors, Journal of Biological Chemistry, vol.285, issue.10, pp.7187-7196, 2010.
DOI : 10.1074/jbc.M109.061861

D. Lauzeille and J. L. Marchand, Consommation de tabac par catégorie socioprofessionnelle et secteur d'activité, 2010.

D. S. Lawrence and J. Niu, Protein Kinase InhibitorsThe Tyrosine-Specific Protein Kinases, Pharmacology & Therapeutics, vol.77, issue.2, pp.81-114, 1998.
DOI : 10.1016/S0163-7258(97)00052-1

J. H. Lee and S. R. Hart, Histone deacetylase activity is required for embryonic stem cell differentiation, genesis, vol.29, issue.1, pp.32-38, 2004.
DOI : 10.1002/gene.10250

J. H. Lee and E. G. Jeong, Inhibition of histone deacetylase 10 induces thioredoxin-interacting protein and causes accumulation of reactive oxygen species in SNU-620 human gastric cancer cells, Molecules and Cells, vol.98, issue.2, pp.107-112, 2010.
DOI : 10.1007/s10059-010-0094-z

J. S. Lee and K. Park, A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung, J Thorac Oncol, vol.4, issue.1, p.283, 2009.

Y. S. Lee and K. H. Lim, The Cytoplasmic Deacetylase HDAC6 Is Required for Efficient Oncogenic Tumorigenesis, Cancer Research, vol.68, issue.18, pp.7561-7569, 2008.
DOI : 10.1158/0008-5472.CAN-08-0188

H. Li and H. Zhu, Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis, Cell, vol.94, issue.4, pp.491-501, 1998.
DOI : 10.1016/S0092-8674(00)81590-1

J. Li and Q. Lin, Specific targeting and constitutive association of histone deacetylase complexes during transcriptional repression, Genes & Development, vol.16, issue.6, pp.687-692, 2002.
DOI : 10.1101/gad.962502

L. Y. Li and X. Luo, Endonuclease G is an apoptotic DNase when released from mitochondria, Nature, vol.412, issue.6842, pp.95-99, 2001.
DOI : 10.1038/35083620

H. Liu and Q. Hu, Histone deacetylase 11 regulates oligodendrocyte-specific gene expression and cell development in OL-1 oligodendroglia cells, Glia, vol.77, issue.1, pp.1-12, 2009.
DOI : 10.1002/glia.20729

J. Lu and T. A. Mckinsey, Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases, Proceedings of the National Academy of Sciences, vol.97, issue.8, pp.4070-4075, 2000.
DOI : 10.1073/pnas.080064097

G. Lyratzopoulos and G. A. Abel, Variation in advanced stage at diagnosis of lung and female breast cancer in an English region 2006???2009, British Journal of Cancer, vol.7, issue.6, pp.1068-1075, 2006.
DOI : 10.1038/sj.bjc.6602506

M. Malvezzi and P. Bertuccio, European cancer mortality predictions for the year 2012, Annals of Oncology, vol.23, issue.4, pp.1044-1052, 2012.
DOI : 10.1093/annonc/mds024

A. Marcilla and I. Martinez, Comparative study of the main characteristics and composition of the mainstream smoke of ten cigarette brands sold in Spain, Food and Chemical Toxicology, vol.50, issue.5, pp.1317-1333, 2012.
DOI : 10.1016/j.fct.2012.01.046

M. Martin and R. Kettmann, Class IIa histone deacetylases: regulating the regulators, Oncogene, vol.15, issue.37, pp.5450-5467, 2007.
DOI : 10.1073/pnas.250494697

N. Martini, Surgical treatment of non-small cell lung cancer by stage, Seminars in Surgical Oncology, vol.36, issue.5, pp.248-254, 1990.
DOI : 10.1002/ssu.2980060505

M. Maemondo and A. Inoue, Gefitinib or Chemotherapy for Non???Small-Cell Lung Cancer with Mutated EGFR, New England Journal of Medicine, vol.362, issue.25, pp.2380-2388, 2010.
DOI : 10.1056/NEJMoa0909530

J. Massague and A. Pandiella, Membrane-Anchored Growth Factors, Annual Review of Biochemistry, vol.62, issue.1, pp.515-541, 1993.
DOI : 10.1146/annurev.bi.62.070193.002503

E. Massarelli and M. Varella-garcia, KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer, Clinical Cancer Research, vol.13, issue.10, pp.2890-2896, 2007.
DOI : 10.1158/1078-0432.CCR-06-3043

A. Matsuyama and T. Shimazu, In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation, The EMBO Journal, vol.21, issue.24, pp.6820-6831, 2002.
DOI : 10.1093/emboj/cdf682

M. P. Mattson, Pathways towards and away from Alzheimer's disease, Nature, vol.22, issue.7000, pp.631-639, 2004.
DOI : 10.1016/j.molcel.2003.08.005

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3091392

T. A. Mckinsey and C. L. Zhang, MEF2: a calcium-dependent regulator of cell division, differentiation and death, Trends in Biochemical Sciences, vol.27, issue.1, pp.40-47, 2002.
DOI : 10.1016/S0968-0004(01)02031-X

O. Micheau and E. Solary, Fas Ligand-independent, FADD-mediated Activation of the Fas Death Pathway by Anticancer Drugs, Journal of Biological Chemistry, vol.274, issue.12, pp.7987-7992, 1999.
DOI : 10.1074/jbc.274.12.7987

P. J. Miettinen and J. E. Berger, Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor, Nature, vol.376, issue.6538, pp.337-341, 1995.
DOI : 10.1038/376337a0

C. T. Miller and L. Lin, Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma, Oncogene, vol.88, issue.3, pp.409-418, 2006.
DOI : 10.1038/sj.onc.1209057

T. Miyashita and S. Krajewski, Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo, Oncogene, vol.9, issue.6, pp.1799-1805, 1994.

T. Miyashita and J. C. Reed, Tumor suppressor p53 is a direct transcriptional activator of the human bax gene, Cell, vol.80, issue.2, pp.293-299, 1995.

T. S. Mok and Y. L. Wu, Gefitinib or Carboplatin???Paclitaxel in Pulmonary Adenocarcinoma, New England Journal of Medicine, vol.361, issue.10, pp.947-957, 2009.
DOI : 10.1056/NEJMoa0810699

F. Morgillo and W. Y. Kim, Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non small Cell Lung Cancer Cells to Treatment with Gefitinib, Clinical Cancer Research, vol.13, issue.9, pp.2795-2803, 2007.
DOI : 10.1158/1078-0432.CCR-06-2077

F. Morgillo and J. K. Woo, Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib, Cancer Research, vol.66, issue.20, pp.10100-10111, 2006.
DOI : 10.1158/0008-5472.CAN-06-1684

T. Mitsudomi and S. Morita, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, The Lancet Oncology, vol.11, issue.2, pp.121-128, 2010.
DOI : 10.1016/S1470-2045(09)70364-X

K. Noma and C. D. Allis, Transitions in Distinct Histone H3 Methylation Patterns at the Heterochromatin Domain Boundaries, Science, vol.293, issue.5532, pp.1150-1155, 2001.
DOI : 10.1126/science.1064150

N. Normanno and A. De-luca, Epidermal growth factor receptor (EGFR) signaling in cancer, Gene, vol.366, issue.1, pp.2-16, 2006.
DOI : 10.1016/j.gene.2005.10.018

I. Oehme and H. E. Deubzer, Targeting of HDAC8 and investigational inhibitors in neuroblastoma, Expert Opinion on Investigational Drugs, vol.8, issue.3, pp.1605-1617, 2009.
DOI : 10.1073/pnas.0803749105

T. Okabe and I. Okamoto, Differential Constitutive Activation of the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer Cells Bearing EGFR Gene Mutation and Amplification, Cancer Research, vol.67, issue.5, pp.2046-2053, 2007.
DOI : 10.1158/0008-5472.CAN-06-3339

M. A. Olayioye and R. M. Neve, NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer, The EMBO Journal, vol.19, issue.13, pp.3159-3167, 2000.
DOI : 10.1093/emboj/19.13.3159

H. Osada and Y. Tatematsu, Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients, International Journal of Cancer, vol.112, issue.1, pp.26-32, 2004.
DOI : 10.1002/ijc.20395

K. Ozaki and M. Kosugi, Blockade of the ERK or PI3K???Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib, Biochemical and Biophysical Research Communications, vol.391, issue.4, pp.1610-1615, 2010.
DOI : 10.1016/j.bbrc.2009.12.086

W. Pao and V. A. Miller, Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non???Small-Cell Lung Cancer: Current Knowledge and Future Directions, Journal of Clinical Oncology, vol.23, issue.11, pp.2556-2568, 2005.
DOI : 10.1200/JCO.2005.07.799

W. Pao and V. A. Miller, Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain, PLoS Medicine, vol.9, issue.3, p.73, 2005.
DOI : 10.1371/journal.pmed.0020073.sd001

P. Lamelas, I. , and J. Arca, Directed Therapies in Lung Cancer: New Hope?, Arch Bronconeumol, 2012.

L. Paz-ares and J. Sanchez, A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR), ASCO annual Meeting, 2006.

M. E. Peter and P. H. Krammer, The CD95(APO-1/Fas) DISC and beyond, Cell Death and Differentiation, vol.10, issue.1, pp.26-35, 2003.
DOI : 10.1038/sj.cdd.4401186

R. Perez-soler, HER1/EGFR Targeting: Refining the Strategy, The Oncologist, vol.9, issue.1, pp.58-67, 2004.
DOI : 10.1634/theoncologist.9-1-58

M. J. Pinkoski and D. R. Green, Lymphocyte apoptosis: refining the paths to perdition, Current Opinion in Hematology, vol.9, issue.1, pp.43-49, 2002.
DOI : 10.1097/00062752-200201000-00008

N. Prenzel and O. M. Fischer, The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification, Endocrine Related Cancer, vol.8, issue.1, pp.11-31, 2001.
DOI : 10.1677/erc.0.0080011

L. Qin and N. C. Partridge, Stimulation of amphiregulin expression in osteoblastic cells by parathyroid hormone requires the protein kinase A and cAMP response element-binding protein signaling pathway, Journal of Cellular Biochemistry, vol.138, issue.3, pp.632-640, 2005.
DOI : 10.1002/jcb.20550

L. Qin and J. Tamasi, Amphiregulin Is a Novel Growth Factor Involved in Normal Bone Development and in the Cellular Response to Parathyroid Hormone Stimulation, Journal of Biological Chemistry, vol.280, issue.5, pp.3974-3981, 2005.
DOI : 10.1074/jbc.M409807200

M. Reck and L. Crino, Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer, Lung Cancer, vol.63, issue.1, pp.1-9, 2009.
DOI : 10.1016/j.lungcan.2008.05.015

J. C. Reed, Dysregulation of Apoptosis in Cancer, Journal of Clinical Oncology, vol.17, issue.9, pp.2941-2953, 1999.
DOI : 10.1200/JCO.1999.17.9.2941

S. J. Riedl and Y. Shi, Molecular mechanisms of caspase regulation during apoptosis, Nature Reviews Molecular Cell Biology, vol.11, issue.11, pp.897-907, 2004.
DOI : 10.1107/S0021889891004399

S. Roche and M. L. Van-de-wetering, Resumé des caracteistiques du produit Roche 21p Disponible sur www.roche.fr RodenhuisMutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung, N Engl J Med, issue.15, pp.317-929, 1987.

S. Y. Roth and J. M. Denu, Histone Acetyltransferases, Annual Review of Biochemistry, vol.70, issue.1, pp.81-120, 2001.
DOI : 10.1146/annurev.biochem.70.1.81

V. Rusch and J. Baselga, Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung, Cancer Res, vol.53, pp.2379-2385, 1993.

U. Sahin and G. Weskamp, Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands, The Journal of Cell Biology, vol.347, issue.5, pp.769-779, 2004.
DOI : 10.1128/MCB.24.1.96-104.2004

H. Sakurai and T. Tsukamoto, EGF receptor ligands are a large fraction of in vitro branching morphogens secreted by embryonic kidney, Am J Physiol, vol.2733, issue.2, pp.463-472, 1997.

D. S. Salomon and R. Brandt, Epidermal growth factor-related peptides and their receptors in human malignancies, Critical Reviews in Oncology/Hematology, vol.19, issue.3, pp.183-232, 1995.
DOI : 10.1016/1040-8428(94)00144-I

M. Sanchez-cespedes, Dissecting the genetic alterations involved in lung carcinogenesis, Lung Cancer, vol.40, issue.2, pp.111-121, 2003.
DOI : 10.1016/S0169-5002(03)00033-3

R. G. Sangani and A. J. Ghio, Lung injury after cigarette smoking is particle related, Int J Chron Obstruct Pulmon Dis, vol.6, pp.191-198, 2011.

H. Sasaki and K. Endo, EGFR exon 20 insertion mutation in Japanese lung cancer, Lung Cancer, vol.58, issue.3, pp.324-328, 2007.
DOI : 10.1016/j.lungcan.2007.06.024

L. V. Sequist and D. W. Bell, Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.25, issue.5, pp.587-595, 2007.
DOI : 10.1200/JCO.2006.07.3585

L. V. Sequist, R. G. Martins, and R. , Mutations, Journal of Clinical Oncology, vol.26, issue.15, pp.2442-2449, 2008.
DOI : 10.1200/JCO.2007.14.8494

J. H. Schiller and D. Harrington, Comparison of Four Chemotherapy Regimens for Advanced Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.346, issue.2, pp.92-98, 2002.
DOI : 10.1056/NEJMoa011954

L. Schuger and G. R. Johnson, Amphiregulin in lung branching morphogenesis: interaction with heparan sulfate proteoglycan modulates cell proliferation, Development, vol.122, issue.6, pp.1759-1767, 1996.

D. Seigneurin-berny and A. Verdel, Identification of Components of the Murine Histone Deacetylase 6 Complex: Link between Acetylation and Ubiquitination Signaling Pathways, Molecular and Cellular Biology, vol.21, issue.23, pp.8035-8044, 2001.
DOI : 10.1128/MCB.21.23.8035-8044.2001

URL : https://hal.archives-ouvertes.fr/hal-00380090

S. V. Sharma and D. W. Bell, Epidermal growth factor receptor mutations in lung cancer, Nature Reviews Cancer, vol.64, issue.3, pp.169-181, 2007.
DOI : 10.1038/nrc2088

F. A. Shepherd and J. R. Pereira, Erlotinib in Previously Treated Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.353, issue.2, pp.123-132, 2005.
DOI : 10.1056/NEJMoa050753

T. W. Shields, Surgical therapy for carcinoma of the lung, Clin Chest Med, vol.14, issue.1, pp.121-147, 1993.

H. Shigematsu and L. Lin, Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers, JNCI Journal of the National Cancer Institute, vol.97, issue.5, pp.339-346, 2005.
DOI : 10.1093/jnci/dji055

H. Shigematsu and T. Takahashi, Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas, Cancer Research, vol.65, issue.5, pp.1642-1646, 2005.
DOI : 10.1158/0008-5472.CAN-04-4235

N. Shivapurkar and J. Reddy, Apoptosis and lung cancer: A review, Journal of Cellular Biochemistry, vol.64, issue.5, pp.885-898, 2003.
DOI : 10.1002/jcb.10440

M. Shoyab and V. L. Mcdonald, Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7., Proceedings of the National Academy of Sciences, vol.85, issue.17, pp.85-6528, 1988.
DOI : 10.1073/pnas.85.17.6528

M. Sibilia and E. F. Wagner, Strain-dependent epithelial defects in mice lacking the EGF receptor, Science, vol.269, issue.5221, pp.234-238, 1995.
DOI : 10.1126/science.7618085

T. Skorski, ONCOGENIC TYROSINE KINASES AND THE DNA-DAMAGE RESPONSE, Nature Reviews Cancer, vol.2, issue.5, pp.351-360, 2002.
DOI : 10.1038/nrc799

T. Skorski, Genetic Mechanisms of Chronic Myeloid Leukemia Blastic Transformation, Current Hematologic Malignancy Reports, vol.105, issue.2, pp.87-93, 2012.
DOI : 10.1007/s11899-012-0114-5

R. J. Slebos and S. Rodenhuis, The ras gene family in human non-small-cell lung cancer, J Natl Cancer Inst Monogr, issue.13, pp.23-29, 1992.

B. C. Smith and J. M. Denu, Chemical mechanisms of histone lysine and arginine modifications, Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, vol.1789, issue.1, pp.45-57, 2009.
DOI : 10.1016/j.bbagrm.2008.06.005

G. A. Smolen and R. Sordella, Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752, Proceedings of the National Academy of Sciences, vol.103, issue.7, pp.2316-2321, 2006.
DOI : 10.1073/pnas.0508776103

M. Soda and Y. L. Choi, Identification of the transforming EML4???ALK fusion gene in non-small-cell lung cancer, Nature, vol.276, issue.7153, pp.561-566, 2007.
DOI : 10.1038/nature05945

D. B. Sparrow and E. A. Miska, MEF-2 function is modified by a novel co-repressor, MITR, The EMBO Journal, vol.18, issue.18, pp.5085-5098, 1999.
DOI : 10.1093/emboj/18.18.5085

H. R. Stennicke and G. S. Salvesen, Caspases ??? controlling intracellular signals by protease zymogen activation, Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, vol.1477, issue.1-2, pp.299-306, 2000.
DOI : 10.1016/S0167-4838(99)00281-2

D. E. Sterner and S. L. Berger, Acetylation of Histones and Transcription-Related Factors, Microbiology and Molecular Biology Reviews, vol.64, issue.2, pp.435-459, 2000.
DOI : 10.1128/MMBR.64.2.435-459.2000

T. E. Stinchcombe and M. A. Socinski, Current Treatments for Advanced Stage Non-Small Cell Lung Cancer, Proceedings of the American Thoracic Society, vol.6, issue.2, pp.233-241, 2009.
DOI : 10.1513/pats.200809-110LC

L. M. Strawn and L. K. Shawver, Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials, Expert Opinion on Investigational Drugs, vol.38, issue.4, pp.553-573, 1998.
DOI : 10.1126/science.276.5314.955

C. Subramanian and J. A. Jarzembowski, HDAC6 Deacetylates Ku70 and Regulates Ku70-Bax Binding in Neuroblastoma, Neoplasia, vol.13, issue.8, pp.726-734, 2011.
DOI : 10.1593/neo.11558

URL : http://doi.org/10.1593/neo.11558

M. Sun and C. Behrens, HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors, Clinical Cancer Research, vol.15, issue.15, pp.4829-4837, 2009.
DOI : 10.1158/1078-0432.CCR-08-2921

S. W. Sunnarborg and C. L. Hinkle, Tumor Necrosis Factor-?? Converting Enzyme (TACE) Regulates Epidermal Growth Factor Receptor Ligand Availability, Journal of Biological Chemistry, vol.277, issue.15, pp.12838-12845, 2002.
DOI : 10.1074/jbc.M112050200

S. A. Susin and H. K. Lorenzo, Molecular characterization of mitochondrial apoptosisinducing factor, Nature, vol.397, issue.6718, pp.441-446, 1999.

H. Swaisland and A. Laight, Pharmacokinetics and Tolerability of the Orally Active Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Healthy Volunteers, Clinical Pharmacokinetics, vol.19, issue.4, pp.297-306, 2001.
DOI : 10.2165/00003088-200140040-00005

H. C. Swaisland and M. V. Cantarini, Exploring the Relationship Between Expression of Cytochrome P450??Enzymes and Gefitinib Pharmacokinetics, Clinical Pharmacokinetics, vol.27, issue.10, pp.633-644, 2006.
DOI : 10.2165/00003088-200645060-00006

H. C. Swaisland and M. Ranson, Pharmacokinetic Drug Interactions of Gefitinib with Rifampicin, Itraconazole and Metoprolol, Clinical Pharmacokinetics, vol.54, issue.10, pp.1067-1081, 2005.
DOI : 10.2165/00003088-200544100-00005

T. Takano and Y. Ohe, Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.23, issue.28, pp.6829-6837, 2005.
DOI : 10.1200/JCO.2005.01.0793

K. Tamura and I. Okamoto, Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403), British Journal of Cancer, vol.2, issue.5, pp.907-914, 2008.
DOI : 10.2353/jmoldx.2006.050104

N. Thatcher and A. Chang, Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer), The Lancet, vol.366, issue.9496, pp.1527-1537, 2005.
DOI : 10.1016/S0140-6736(05)67625-8

T. Van-den-broeck and A. , Aspects épigénétiques des cancers broncho-pulmonaires et implication de l'histone acétyltransférase Tip60, 2009.

W. G. and R. Chalmers-redman, Apoptosis in Parkinson's disease: signals for neuronal degradation, Ann Neurol, vol.53, issue.3, pp.61-70, 2003.

L. Thiberville and C. Paris, Epidémiologie et facteurs de risque des cancers bronchiques primitifs, EMCpneumologie, vol.1, issue.1, pp.7-18, 2004.
DOI : 10.1016/s1155-195x(04)74551-x

C. B. Thompson, Apoptosis in the pathogenesis and treatment of disease, Science, vol.267, issue.5203, pp.1456-1462, 1995.
DOI : 10.1126/science.7878464

D. W. Threadgill and A. A. Dlugosz, Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype, Science, vol.269, issue.5221, pp.230-234, 1995.
DOI : 10.1126/science.7618084

N. Torring and B. S. Sorensen, Amphiregulin is expressed in primary cultures of prostate myofibroblasts, fibroblasts, epithelial cells, and in prostate tissue, Prostate Cancer and Prostatic Diseases, vol.1, issue.5, pp.262-267, 1998.
DOI : 10.1038/sj.pcan.4500250

W. D. Travis and E. Brambilla, International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma, Journal of Thoracic Oncology, vol.6, issue.2, pp.244-285, 2011.
DOI : 10.1097/JTO.0b013e318206a221

URL : https://hal.archives-ouvertes.fr/inserm-00561753

Y. Umekita and Y. Ohi, Co-expression of epidermal growth factor receptor and transforming growth factor-?? predicts worse prognosis in breast-cancer patients, International Journal of Cancer, vol.89, issue.6, pp.484-491, 2000.
DOI : 10.1002/1097-0215(20001120)89:6<484::AID-IJC3>3.0.CO;2-S

S. Van-cruchten, W. Van-den, and . Broeck, Morphological and Biochemical Aspects of Apoptosis, Oncosis and Necrosis, Anatomia, Histologia, Embryologia: Journal of Veterinary Medicine Series C, vol.68, issue.4, pp.214-223, 2002.
DOI : 10.1093/emboj/16.17.5386

T. J. Velu, Structure, function and transforming potential of the epidermal growth factor receptor, Molecular and Cellular Endocrinology, vol.70, issue.3, pp.205-216, 1990.
DOI : 10.1016/0303-7207(90)90211-P

A. Verdel and S. Curtet, Active maintenance of mHDA2/mHDAC6 histone-deacetylase in the cytoplasm, Current Biology, vol.10, issue.12, pp.747-749, 2000.
DOI : 10.1016/S0960-9822(00)00542-X

A. Verdel and S. Khochbin, Identification of a New Family of Higher Eukaryotic Histone Deacetylases: COORDINATE EXPRESSION OF DIFFERENTIATION-DEPENDENT CHROMATIN MODIFIERS, Journal of Biological Chemistry, vol.274, issue.4, pp.2440-2445, 1999.
DOI : 10.1074/jbc.274.4.2440

S. Vignot and B. Besse, [Gemcitabine and non small-cell lung cancer], Cancer 94 Spec No Actualites, pp.95-103, 2007.

A. Villagra and F. Cheng, The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance, Nature Immunology, vol.1, issue.1, pp.92-100, 2009.
DOI : 10.1038/ni.1673

M. Volm and P. Drings, Prognostic significance of the expression of c-fos, c-jun and c-erbB-1 oncogene products in human squamous cell lung carcinomas, Journal of Cancer Research and Clinical Oncology, vol.6, issue.9, pp.507-510, 1993.
DOI : 10.1007/BF01686458

P. A. Wade, Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin, Human Molecular Genetics, vol.10, issue.7, pp.693-698, 2001.
DOI : 10.1093/hmg/10.7.693

W. H. Ward and P. N. Cook, Epidermal growth factor receptor tyrosine kinase, Biochemical Pharmacology, vol.48, issue.4, pp.659-666, 1994.
DOI : 10.1016/0006-2952(94)90042-6

C. M. Warren and R. Landgraf, Signaling through ERBB receptors: Multiple layers of diversity and control, Cellular Signalling, vol.18, issue.7, pp.923-933, 2006.
DOI : 10.1016/j.cellsig.2005.12.007

M. Weil and M. C. Raff, Caspase activation in the terminal differentiation of human epidermal keratinocytes, Current Biology, vol.9, issue.7, pp.361-364, 1999.
DOI : 10.1016/S0960-9822(99)80162-6

A. Wells, EGF receptor, The International Journal of Biochemistry & Cell Biology, vol.31, issue.6, pp.637-643, 1999.
DOI : 10.1016/S1357-2725(99)00015-1

J. J. Westendorf and S. K. Zaidi, Runx2 (Cbfa1, AML-3) Interacts with Histone Deacetylase 6 and Represses the p21CIP1/WAF1 Promoter, Molecular and Cellular Biology, vol.22, issue.22, pp.7982-7992, 2002.
DOI : 10.1128/MCB.22.22.7982-7992.2002

W. and M. Turmaine, Global status report on noncommunicable diseases World Health Organization 176p WoodMesenchymal cells engulf and clear apoptotic footplate cells in macrophageless PU.1 null mouse embryos, WHO Development, vol.127, issue.24, pp.5245-5252, 2000.

W. S. Xu and R. B. Parmigiani, Histone deacetylase inhibitors: molecular mechanisms of action, Oncogene, vol.3, issue.37, pp.5541-5552, 2007.
DOI : 10.1016/j.bbrc.2005.12.144

X. M. Yin, Signal transduction mediated by Bid, a pro-death Bcl-2 family proteins, connects the death receptor and mitochondria apoptosis pathways, Cell Research, vol.21, issue.3, pp.161-167, 2000.
DOI : 10.1084/jem.182.5.1223

K. Yoshida and Y. Yatabe, Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer, Journal of Thoracic Oncology, vol.2, issue.1, pp.22-30, 2007.
DOI : 10.1097/01243894-200701000-00006

A. You and J. K. Tong, CoREST is an integral component of the CoREST- human histone deacetylase complex, Proceedings of the National Academy of Sciences, vol.98, issue.4, pp.1454-1458, 2001.
DOI : 10.1073/pnas.98.4.1454

C. H. Yun and K. E. Mengwasser, The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP, Proceedings of the National Academy of Sciences, vol.105, issue.6, pp.2070-2075, 2008.
DOI : 10.1073/pnas.0709662105

R. Zandi and A. B. Larsen, Mechanisms for oncogenic activation of the epidermal growth factor receptor, Cellular Signalling, vol.19, issue.10, pp.2013-2023, 2007.
DOI : 10.1016/j.cellsig.2007.06.023

Y. Zhang and B. Gilquin, Two Catalytic Domains Are Required for Protein Deacetylation, Journal of Biological Chemistry, vol.281, issue.5, pp.2401-2404, 2006.
DOI : 10.1074/jbc.C500241200

URL : https://hal.archives-ouvertes.fr/inserm-00176759

Y. Zhang and N. Li, HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo, The EMBO Journal, vol.22, issue.5, pp.1168-1179, 2003.
DOI : 10.1093/emboj/cdg115

Y. Zhang and H. H. Ng, Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation, Genes & Development, vol.13, issue.15, pp.1924-1935, 1999.
DOI : 10.1101/gad.13.15.1924

L. Zhong and M. S. Goldberg, Exposure to environmental tobacco smoke and the risk of lung cancer: a meta-analysis, Lung Cancer, vol.27, issue.1, pp.3-18, 2000.
DOI : 10.1016/S0169-5002(99)00093-8

H. Zou and Y. Wu, Characterization of the two catalytic domains in histone deacetylase 6, Biochemical and Biophysical Research Communications, vol.341, issue.1, pp.45-50, 2006.
DOI : 10.1016/j.bbrc.2005.12.144